Actively Recruiting
Sleep, Diabetic Retinopathy and Melatonin
Led by University of Illinois at Chicago · Updated on 2026-04-21
42
Participants Needed
1
Research Sites
277 weeks
Total Duration
On this page
Sponsors
U
University of Illinois at Chicago
Lead Sponsor
U
University of Chicago
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study explores the use of melatonin in patients with diabetic retinopathy
CONDITIONS
Official Title
Sleep, Diabetic Retinopathy and Melatonin
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinically diagnosed type 2 diabetes, taking anti-diabetes medications or history of elevated A1C ≥6.5%
- Age between 40 and 65 years
- Diabetic retinopathy of at least moderate severity
You will not qualify if you...
- Current use of melatonin
- Use of antidepressants or antipsychotics
- Illicit drug use
- Night shift work or travel beyond 2 time zones in the month before enrollment
- End stage renal disease requiring renal replacement therapy
- History of stroke or transient ischemic attacks
- History of dementia or memory impairment
- Uncontrolled congestive heart failure or recent hospitalization for cardiac condition within 6 months
- Chronic obstructive pulmonary disease requiring oxygen
- Severe chronic liver disease such as cirrhosis
- Ongoing treatment for major medical problems such as cancer
- History of severe hypoglycemia with episodes requiring assistance within the past six months
- Significant depressive symptoms
- Untreated severe obstructive sleep apnea (AHI ≥ 30 events/hour)
- Uncontrolled hypertension (blood pressure ≥ 160/100 mmHg)
- Uncontrolled diabetes (A1C ≥ 11%)
- Abnormal thyroid stimulating hormone (TSH)
- Abnormal liver function with AST or ALT >3 times upper limits of normal
- Use of sedatives and hypnotics
- Clinically significant epiretinal membranes, lens opacities, cystoid macular edema, iris neovascularization, iris atrophy, asymmetrically shaped pupil, nuclear sclerotic, posterior subcapsular, or cortical lens opacities greater than 2+
- History of pan-retinal photocoagulation
- Hemoglobin less than 11.5 g/dL in women and less than 13.5 g/dL in men
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Illinois at Chicago
Chicago, Illinois, United States, 60612
Actively Recruiting
Research Team
S
Sirimon Reutrakul
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here